Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy

Journal of Gene Medicine

Volumn 13, Issue 12, 2011, Pages 680-691

  Xie, Xinhua ^a   Guo, Jiaoli ^a   Kong, Yanan ^a   Xie, Gene Xianquan ^a   Li, Laishen ^a   Lv, Ning ^a   Xiao, Xiangsheng ^a   Tang, Jun ^a   Wang, Xi ^a   Liu, Peng ^a   Yang, Mingtian ^a   Xie, Zeming ^a   Wei, Weidong ^a   Xie, Xiaoming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

E. coli PNP; Fludarabine; Probasin promoter; Prostate cancer; Transcriptional targeting

Indexed keywords

ADENOVIRUS VECTOR; FLUDARABINE PHOSPHATE; MESSENGER RNA; METRIBOLONE; PURINE NUCLEOSIDE PHOSPHORYLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; ESCHERICHIA COLI; GENE CONSTRUCT; GENETIC TRANSFECTION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE SPECIFICITY; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ARRESTINS; CELL DEATH; CELL LINE, TUMOR; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; METRIBOLONE; MICE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE; RATS; VIDARABINE PHOSPHATE;

EID: 84255178512     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1620     Document Type: Article

References (60)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439.
3. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107-118.
4. Andriole GL, Crawford ED, Grubb RR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
5. Brawley OW, Ankerst DP, Thompson IM. Screening for prostate cancer. CA Cancer J Clin 2009; 59: 264-273.
6. Ahn M, Lee SJ, Li X, et al. Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter. Cancer Gene Ther 2009; 16: 73-82.
7. D'Amico AV, Moran BJ, Braccioforte MH, et al. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009; 27: 3923-3928.
8. Abdollah F, Sun M, Schmitges J, et al. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur Urol 2011; 60: E47-E48.
9. Madan RA, Pal SK, Sartor O, et al. Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res 2011; 17: 3892-3902.
10. Nasu Y, Saika T, Ebara S, et al. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 2007; 15: 834-840.
11. Xie X, Xia W, Li Z, et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 2007; 12: 52-65.
12. Xie X, Hsu JL, Choi MG, et al. A novel hTERT promoter-driven E1 A therapeutic for ovarian cancer. Mol Cancer Ther 2009; 8: 2375-2382.
13. Watanabe M, Nasu Y, Kashiwakura Y, et al. Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth. Hum Gene Ther 2005; 16: 699-710.
14. Li H, Qi Y, Li C, et al. Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther 2009; 8: 3255-3265.
15. Onion D, Patel P, Pineda RG, et al. Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer. Hum Gene Ther 2009; 20: 1249-1258.
16. Harzstark AL, Small EJ. Immunotherapeutics in development for prostate cancer. Oncologist 2009; 14: 391-398.
17. Pantuck AJ, Matherly J, Zisman A, et al. Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum Gene Ther 2002; 13: 777-789.
18. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003; 14: 227-241.
19. Ayala G, Satoh T, Li R, et al. Biological response determinants in HSV-tk+ganciclovir gene therapy for prostate cancer. Mol Ther 2006; 13: 716-728.
20. Lee JT, Lehmann BD, Terrian DM, et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008; 7: 1745-1762.
21. Shaheen FS, Znojek P, Fisher A, et al. Targeting the DNA double strand break repair machinery in prostate cancer. PLoS One 2011; 6: E20311.
22. Ekblad M, Hallden G. Adenovirus-based therapy for prostate cancer. Curr Opin Mol Ther 2010; 12: 421-431.
23. Schenk E, Essand M, Bangma CH, et al. Clinical adenoviral gene therapy for prostate cancer. Hum Gene Ther 2010; 21: 807-813.
24. Lu Y. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. Adv Drug Deliv Rev 2009; 61: 572-588.
25. Wen Y, Giri D, Yan DH, et al. Prostate-specific antitumor activity by probasin promoter-directed p202 expression. Mol Carcinog 2003; 37: 130-137.
26. Sun Q, Yu X, Degraff DJ, et al. Upstream stimulatory factor 2, a novel FoxA1-interacting protein, is involved in prostate-specific gene expression. Mol Endocrinol 2009; 23: 2038-2047.
27. Latham JP, Searle PF, Mautner V, et al. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000; 60: 334-341.
28. Lee CY, Bu LX, Rennie PS, et al. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. Cancer Gene Ther 2007; 14: 652-660.
29. Jensen KF, Nygaard P. Purine nucleoside phosphorylase from Escherichia coli and Salmonella typhimurium. Purification and some properties. Eur J Biochem 1975; 51: 253-265.
30. Kikuchi E, Menendez S, Ozu C, et al. Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther 2007; 14: 279-286.
31. Tai CK, Wang W, Lai YH, et al. Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene. Cancer Gene Ther 2010; 17: 614-623.
32. Kakinuma H, Bergert ER, Spitzweg C, et al. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003; 63: 7840-7844.
33. Wang Z, Luque RM, Kineman RD, et al. Disruption of growth hormone signaling retards prostate carcinogenesis in the Probasin/TAg rat. Endocrinology 2008; 149: 1366-1376.
34. Andriani F, Nan B, Yu J, et al. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst 2001; 93: 1314-1324.
35. Xie X, Zhao X, Liu Y, et al. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Hum Gene Ther 2001; 12: 549-561.
36. Xie X, Zhao X, Liu Y, et al. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res 2001; 61: 6795-6804.
37. Hardy S, Kitamura M, Harris-Stansil T, et al. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997; 71: 1842-1849.
38. Chillon M, Alemany R. Methods to construct recombinant adenovirus vectors. Meth Mol Biol 2011; 737: 117-138.
39. Xie X, Forsmark CE, Lau JY. Effect of bile and pancreatic juice on adenoviral-mediated gene delivery: implications on the feasibility of gene delivery through ERCP. Dig Dis Sci 2000; 45: 230-236.
40. Seethammagari MR, Xie X, Greenberg NM, et al. EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action. Cancer Res 2006; 66: 6199-6209.
41. Kochanek S, Gansbacher B. Prostate cancer gene therapy: attempts to innovate. Hum Gene Ther 2010; 21: 791.
42. Maatta AM, Samaranayake H, Pikkarainen J, et al. Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr Gene Ther 2009; 9: 356-367.
43. Liu L, Wang S, Shan B, et al. Advances in viral-vector systemic cytokine gene therapy against cancer. Vaccine 2010; 28: 3883-3887.
44. Thompson TC, Rodriguez R. Gene therapy prolongs PSA doubling time in prostate cancer patients. Mol Ther 2007; 15: 442-443.
45. Muthana M, Giannoudis A, Scott SD, et al. Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res 2011; 71: 1805-1815.
46. Hekim C, Leinonen J, Narvanen A, et al. Novel peptide inhibitors of human kallikrein 2. J Biol Chem 2006; 281: 12555-12560.
47. Nakajima T, Mitsunaga M, Bander NH, et al. Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA)-positive tumors using the quenched humanized J591 antibody-ICG conjugate. Bioconjug Chem 2011; 22: 1700-1705.
48. Hillier SM, Kern AM, Maresca KP, et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med 2011; 52: 1087-1093.
49. Zhang X, Ling MT, Wang Q, et al. Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. J Biol Chem 2007; 282: 33284-33294.
50. Beltinger C, Fulda S, Kammertoens T, et al. Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis. Cancer Res 2000; 60: 3212-3217.
51. Wang Y, Canine BF, Hatefi A. HSV-TK/GCV cancer suicide gene therapy by a designed recombinant multifunctional vector. Nanomedicine 2011; 7: 193-200.
52. Hong JS, Waud WR, Levasseur DN, et al. Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res 2004; 64: 6610-6615.
53. Chaudhary K, Ting LM, Kim K, et al. Toxoplasma gondii purine nucleoside phosphorylase biochemical characterization, inhibitor profiles, and comparison with the Plasmodium falciparum ortholog. J Biol Chem 2006; 281: 25652-25658.
54. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988; 29: 152-163.
55. Bennour E, Ferrand C, Remy-Martin JP, et al. Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance. Hum Gene Ther 2008; 19: 699-709.
56. Krohne TU, Shankara S, Geissler M, et al. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology 2001; 34: 511-518.
57. Sanefuji K, Taketomi A, Iguchi T, et al. Significance of DNA polymerase delta catalytic subunit p125 induced by mutant p53 in the invasive potential of human hepatocellular carcinoma. Oncology-Basel 2010; 79: 229-237.
58. Lim SO, Park YM, Kim HS, et al. Notch1 differentially regulates oncogenesis by wildtype p53 overexpression and p53 mutation in grade III hepatocellular carcinoma. Hepatology 2011; 53: 1352-1362.
59. Voeks D, Martiniello-Wilks R, Madden V, et al. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther 2002; 9: 759-768.
60. Song W, Dong Z, Jin T, et al. Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells. Cancer Gene Ther 2008; 15: 667-675.